Bulk Orders 20+ bottles
Volume pricing applies automatically from three bottles and reaches 20% at twenty. Larger runs, institutional supply and custom timelines get a quote.
Ask about bulk
Reproductive Research
Transdermal Y-134 is a research solution. Each 30ML bottle holds 20MG per mL, or 600MG in total. Labs study it as a selective estrogen receptor modulator (SERM). Topics include ERα signaling, ERβ selectivity, estrogen receptor binding and endocrine pathway models.
Bundle & save
Referral program · researchers save 10%, you earn 15% backThe compounds researchers order most, by verified order volume.
More ways to save
Volume pricing applies automatically from three bottles and reaches 20% at twenty. Larger runs, institutional supply and custom timelines get a quote.
Ask about bulkImportant research notice
Not for human, veterinary, or food use. This product is sold exclusively for laboratory research purposes. It is not intended to diagnose, treat, cure, or prevent any disease, and has not been evaluated by the FDA.
All referenced publications and registries are sourced from peer-reviewed journals and official registries. They are provided for educational reference only and are not product claims.
By purchasing, you confirm you are a qualified researcher and will handle this product in accordance with all applicable laws and regulations.
Dermal preparation
Transdermal Y-134 is a research solution. Each 30ML bottle holds 20MG per mL, or 600MG in total. Labs study it as a selective estrogen receptor modulator (SERM). Topics include ERα signaling, ERβ selectivity, estrogen receptor binding and endocrine pathway models.
It comes as a finished solution with the strength on the label. Each batch gets an in-house QA check, and our own team ships every order.
| Compound | Y-134 (also written Y134) |
|---|---|
| Strength | 20MG/ML |
| Volume | 30ML |
| Total content | 600MG |
| Format | transdermal-format research solution |
Y-134 is a synthetic SERM. A 2007 study tested it in reporter cells that carried either ERα or ERβ. It acted as a potent blocker (antagonist) at both receptors. Its estimated IC50 was 0.52 nM at ERα and 2.94 nM at ERβ (Ning et al., 2007).
Research interest in Y-134 centers on how one compound acts at each type of estrogen receptor. Studies look at signaling at each receptor and at endocrine response models, under controlled lab conditions.
Finished research solutions need more care than a basic listing. For each batch, we review the strength label, the bottle size and the stated total amount. We also check the formula, how the liquid looks, the records and the storage needs. Packing matters too. Each batch must pass our in-house QA before release.
You should be able to check the standards we describe. Learn more about the outside labs we work with: ILS Labs and Chromate.
Y-134 (20MG/ML) research guide
Retain the product label and lot number with the research record. Review the matching certificate of analysis for test coverage and reported results. Identity, analytical purity, measured content, sterility and endotoxin testing are distinct assessments; one does not establish the others.
Follow the supplied label and your laboratory’s validated handling and storage procedures. Record the vehicle, concentration and preparation date where relevant. Dry-material stability does not establish the shelf life of a prepared solution.
Concentration is the stated amount per mL; total content also depends on the container volume. A per-spray amount requires a verified pump output and must not be inferred from concentration alone. Check each component separately for a blend.
Open the linked certificate for the assigned lot or use the COA portal. Check sample identity, methods, date and reported measurements. A report for another lot or formulation is not a substitute.
A synthetic raloxifene analog, not a peptide, that a 2007 study from the Institute of Materia Medica in Shanghai described as "a novel selective oestrogen receptor modulator derived from raloxifene". PubChem lists Y134 and Y-134 as names for [6-hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl]-[4-(4-propan-2-ylpiperazin-1-yl)phenyl]methanone, C₂₈H₂₈N₂O₃S at 472.6 g/mol.
By one side chain. Both are [6-hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl] phenyl ketones, but where raloxifene's phenyl ring carries a 2-(piperidin-1-yl)ethoxy group, Y-134's carries a 4-isopropylpiperazin-1-yl group (PubChem). In CV-1 reporter cells, Y-134 acted as an estrogen receptor antagonist, with IC50 values of 0.52 nM at ERα and 2.94 nM at ERβ, comparable to raloxifene's.
Cells and animals. A PubMed search on 15 October 2026 for Y134 with estrogen-receptor or raloxifene terms returned five records, covering CV-1 reporter cells, MCF-7, T47D and MDA-MB-231 breast cancer cells, hepatoma cells, primary human vaginal epithelial cells, ovariectomized rats, rat dopamine neurons, zebrafish embryos and a mouse retinal degeneration model. Drugs@FDA lists no Y-134 product.
This page sells Y-134 as a research solution supplied at 20MG/ML in a 30ML bottle, providing 600MG total Y-134 content. It is sold exclusively for laboratory research purposes, not for human, veterinary, or food use, and ships from the US West Coast, by FedEx 2-Day shipping.
The current certificate is matched to the selected product option and assigned shipping batch.
Enable JavaScript to view the certificate for your selected option.
We share visit and purchase data with advertising partners to measure and show ads. Some US state laws, including California's, call that a sale or sharing of personal information. You can turn it off for this browser.
Ad sharing is on in this browser.
Saved in this browser only. For your account or other devices, email support@disguisedalpha.com. Privacy Policy